Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01353040 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
A Phase 1 study, sponsored by Sarepta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01353040 is a Phase 1 study that has completed, run by Sarepta Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT01353040, a Phase 1 study, has completed, sponsored by Sarepta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
Interventions
- DRUG Placebo
- DRUG AVI-6003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01353040
The ClinicalTrials.gov registry entry for NCT01353040 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01353040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01353040 about?
NCT01353040 is a clinical study titled "Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus". The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
What is the current status of trial NCT01353040?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-05. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01353040?
The interventions under investigation include: Placebo (DRUG), AVI-6003 (DRUG).
Who is sponsoring clinical trial NCT01353040?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.